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SUMMARY
The balance between cell death and survival, two critical aspects of oncogenic transformation, determines
the outcome of tumorigenesis. Nuclear factor-kB (NF-kB) is a critical regulator of survival; it is induced
by the oncogene Ras and, when inhibited, accounts for the cell death response of Ras-transformed cells.
Here, we show that the signaling adaptor p62 is induced by Ras, its levels are increased in human tumors,
and it is required for Ras-induced survival and transformation. p62/ mice are resistant to Ras-induced
lung adenocarcinomas. p62 is necessary for Ras to trigger IkB kinase (IKK) through the polyubiquitination
of tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6), and its deficiency produces increased
reactive oxygen species (ROS) levels, which account for the enhanced cell death and reduced tumorigenicity
of Ras in the absence of p62.INTRODUCTION
Cancer arises as a consequence of sequential mutations in
genes that play essential roles in the control of cell growth and
proliferation (Hanahan and Weinberg, 2000). These mutations in-
volve the loss of tumor suppressor function and the gain of func-
tion in proto-oncogenes, making tumor cells autonomous of
external proliferation and survival cues (Hanahan and Weinberg,
2000). Among the proto-oncogenes most frequently altered in
human tumors are the small GTPases of the Ras family, which
have been found mutated in at least 25% of human cancers
(Bos, 1989). The Ras oncogene family includes three mem-
bers—H-Ras, K-Ras, and N-Ras—and their activation triggers
a myriad of signaling pathways, only a few of which have been
characterized in detail, such as the Raf-MEK (mitogen-activated
protein kinase [MAPK]/extracellular signal-regulated kinase) and
phosphoinositide (PI) 3-Kinase-Akt signaling cascades (Down-
ward, 2003; Malumbres and Barbacid, 2003).Previous studies showed that Ras activates NF-kB, which is
important for cell survival and tumor transformation because it
suppresses p53-independent Ras-induced cell death (Mayo
et al., 1997). This is a key event because the final outcome of
the oncogenic process is determined by a finely tuned balance
between cell survival and death (Luo et al., 2005). Recent in
vivo data strongly support the role of NF-kB in tumor initiation
and progression in a cell-type dependent manner (for recent re-
views, see Karin, 2006). Thus, the selective knockout of the NF-
kB pathway in epithelial colon cells prevents tumor progression
in a model of inflammation-modulated colon cancer (Greten
et al., 2004). In contrast, the inactivation of NF-kB in the epider-
mis increases tumorigenesis in skin in the apparent absence of
inflammation, likely as the result of increased c-Jun N-terminal
kinase (JNK) activation (Khavari, 2006). On the other hand,
NF-kB inhibition in hepatocytes does not prevent, but rather
enhances, liver cancer in a model of diethylnitrosamine-induced
hepatocarcinogenesis in mice (Maeda et al., 2005). A potentialSIGNIFICANCE
The Ras proto-oncogene has been found mutated in at least 25% of human cancers and is a potent activator of NF-kB,
which is important for cell survival and tumor transformation. However, the mechanism whereby Ras activates NF-kB is
not yet understood. We identify here the signaling adaptor p62 as a critical target of Ras-induced tumorigenesis and NF-
kB activation in vitro and in vivo in a model of Ras-induced lung adenocarcinoma. We show that p62 is induced by Ras, ac-
tivates IKK through TRAF6 polyubiquitination, is overexpressed in human tumors, and is necessary for survival of human
lung adenocarcinoma cells. These findings establish the mechanism for NF-kB activation by Ras and reveal p62 as a key
target in human cancer.Cancer Cell 13, 343–354, April 2008 ª2008 Elsevier Inc. 343
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compensatory proliferation to counteract the increased cell
death in NF-kB-deficient hepatocytes. This cell death activates
an inflammatory response orchestrated by liver macrophages
(Kupffer cells) that secrete proliferative cytokines. This results
in conditions that support the growth and development of surviv-
ing hepatocytes, leading to increased tumorigenesis in the liver
(Maeda et al., 2005). In this case, JNK that is amplified because
of the lack of NF-kB (Chang et al., 2006) is essential for the
enhanced tumorigenicity (Sakurai et al., 1999). This is very inter-
esting considering that Ras-induced apoptosis in fibroblasts, an
important mechanism to restrain tumor development, relies on
the activation of JNK to act as a brake in cell transformation
induced by that oncogene (Kennedy et al., 2003). Therefore,
the mechanism whereby the loss of NF-kB leads to increased
cell death in transformed cells could be accounted for by in-
creased JNK activation in the absence of NF-kB. This model
has been very well studied in TNF-a-activated cells, but whether
it is also valid in Ras transformants is unclear. However, very
recent results show that p38a, another stress-activated MAPK,
is, like JNK, an ROS sensor that negatively regulates Ras-
induced tumorigenesis (Dolado et al., 2007). Therefore, JNK reg-
ulation by NF-kB-mediated ROS production may be considered
a critical mechanism for the control of oncogenic transformation
(Kennedy et al., 2003). However, a critical aspect of Ras-induced
transformation that, as yet, is not fully understood is the mecha-
nism whereby Ras regulates NF-kB.
The IKK complex is central to the activation of NF-kB. It is
composed of a regulatory subunit, termed IKKg or Nemo, and
two catalytic subunits, IKKa and IKKb (Ghosh and Karin,
2002). The genetic inactivation of IKKg or IKKb severely inhibits
the canonical NF-kB pathway in vitro and in vivo, whereas that of
IKKa reveals its role in the alternative NF-kB cascade (Ghosh
and Karin, 2002). The canonical and alternative pathways play
different functions in vivo. Thus, activation of the canonical path-
way results in the phosphorylation and ubiquitination of IkBa,
which is then degraded through the proteasome system (Ghosh
and Karin, 2002). This releases the RelA(p65)/p50 complex that
controls the expression of several genes, including those that
code for ROS scavengers and those that are essential to restrain
JNK and apoptosis (Pham et al., 2004). Previous studies have
implicated the Phox and Bem1p (PB1) domain-containing sig-
naling adaptor p62 in the activation of NF-kB in several cell sys-
tems (Moscat et al., 2006). Studies in knockout (KO) mice reveal
that p62 is induced during the differentiation of osteoclasts and
T cells (Duran et al., 2004; Martin et al., 2006) and is required for
the sustained activation of NF-kB necessary for cell survival
(Martin et al., 2006). Interestingly, p62 has been proposed to
regulate the IkB kinase complex at two levels. First, through its
ability to bind the atypical PKCs (aPKC), PKCz and PKCl/i,
p62 probably favors the phosphorylation of IKKb by the aPKCs
(Lallena et al., 1999). Second, its ability to oligomerize is impor-
tant for the activation and polyubiquitination of TRAF6 (Martin
et al., 2006; Wooten et al., 2005), a relevant event in the activa-
tion of the NF-kB pathway (Chen, 2005). Adapters are critical
components of cell signaling cascades because they confer
specificity to the function of otherwise promiscuous kinases,
such as the aPKCs (Moscat and Diaz-Meco, 2000); therefore,
understanding the role and mechanisms of action of p62 in344 Cancer Cell 13, 343–354, April 2008 ª2008 Elsevier Inc.NF-kB activation and its potential involvement in cancer is of
great interest.
Although the expression of oncogenic Ras chronically activates
NF-kB, the mechanisms that govern the Ras effect are far from
clear. For example, oncogenic Ras has been found to activate
the expression of transfected kB-dependent reporter constructs
(Finco et al., 1997; Mayo et al., 1997), but what has not been es-
tablished yet is whether this is due to Ras actions on the IKK com-
plex (Arsura et al., 2000) or whether Ras triggers a mechanism that
directly targets the phosphorylation of RelA, the transcriptionally
active subunit of NF-kB (Madrid et al., 2001). Because p62 is im-
portant for IKK activation, at least in some cell systems (Duran
et al., 2004; Martin et al., 2006), it is possible that it may orches-
trate a signaling complex that facilitates NF-kB activation by
Ras and, therefore, may be necessary for Ras-induced transfor-
mation. Here, we show that the loss of p62 in embryo fibroblasts
enhances Ras-activated cell death, reducing oncogenic transfor-
mation through impaired NF-kB activation. Importantly, the re-
duced activation of NF-kB observed in the absence of p62 results
in enhanced ROS production, a critical step for the induction of
apoptosis. Ras also promotes the accumulation of p62 mRNA
and protein in embryo fibroblasts (EFs). A similar increase in
p62 levels is observed in several human tumor tissues and in
cell lines where it is essential for proliferation. We provide evi-
dence of the in vivo functional relevance of this phenomenon in
experiments with KO mice demonstrating that the lack of p62 in-
hibits the induction of lung adenocarcinomas by Ras.
RESULTS
Cell-Autonomous Role of p62 in the Survival
of Ras-Transformed Cells
Oncogenic Ras mutations are detected in numerous human
cancers and are known to play a critical role in tumorigenesis
(Bos, 1989). The aPKCs have been proposed to be relevant tar-
gets of Ras in some cell model systems (Diaz-Meco et al., 1994).
In addition, these kinases, along with their adaptor p62, have
been shown to be important regulators of NF-kB, a critical mod-
ulator of cell survival and tumor transformation (Moscat et al.,
2006). These findings led us to address the question of whether
the genetic ablation of p62 would affect tumor transformation of
mouse embryo fibroblasts (MEFs) by oncogenic Ras. Toward
this end, we generated immortal EFs from wild-type (WT) and
p62-deficient mice by infection with a simian virus (SV)-40 large
T retroviral construct. These immortal EFs were infected with
a control retroviral vector or a vector expressing the oncogenic
Ha-RasV12 mutant. Because these vectors contain a hygromy-
cin-selectable marker, infected cells were incubated in the pres-
ence of hygromycin to select Ras-expressing cells for 3 weeks.
The first striking observation was that, although Ras-expressing
WT cells were easily obtained (Figure 1A) with clear characteris-
tics of a transformed phenotype (data not shown), we did not find
p62/ cells with Ras levels similar to those of the p62+/+ cells.
This result suggested negative selection against high Ras-ex-
pressing cells in the absence of p62. This could mean that Ras
transformation in the absence of p62 induces more cell death
than does Ras in the presence of p62, or that it activates cell
cycle progression less efficiently, which would prevent the gen-
eration of p62-deficient high Ras-expressing cells. To explore
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erties of WT and p62 KO immortalized EFs infected with the Ras-
expressing retroviral vector. We measured the number of dead
cells recovered at 7 d postinfection, without antibiotic selection, a
time at which Ras expression reaches a maximum plateau (data
not shown), which is similar in both WT and KO cells (Figure 2A).
Results shown in Figure 1B demonstrate that the number of dead
cells in the p62/ Ras-transformed EF cultures is significantly
higher (10-fold) than in the Ras WT controls (12 ± 2% in KO ver-
sus 1.2 ± 1% in WT cells). These results suggest that cell viability
during Ras-induced transformation is compromised in the ab-
sence of p62, which would explain why we are unable to select
p62/ cells with levels of Ras expression comparable to those
of p62+/+ cells, after a 3-week hygromycin selection period. To
confirm this observation, we performed flow cytometric cell
cycle analysis of p62+/+ and p62/ cells transformed with Ras
as above (Figure 2A). Interestingly, the percentage of cells with
SubG0 DNA content was significantly increased in the Ras-
transformed p62/ cells, compared with the identically treated
p62+/+ controls (Figures 1C and 1D). However, there were no dif-
ferences between both genotypes in terms of the percentage of
cells in G0/G1, S, or G2/M, although the Ras transformants dis-
played a higher proliferative potential (Figures 1E and 1F). These
observations suggest that the loss of p62 prevents some sort of
survival signal required for Ras to efficiently induce cell transfor-
mation. We also used the WT and p62-deficient cells infected
with the control vector or the Ras-expressing construct for 7 d
without hygromycin selection to determine the potential role of
p62 in other critical aspects of Ras-induced transformation.
Even though this protocol generates p62-deficient cells that ex-
press oncogenic Ras at levels comparable to those of the Ras-
transduced WT cells (Figure 2A), and cell death was increased
Figure 1. Ras-Induced Cell Survival Requires p62
(A) EFs from WT or p62-deficient mice immortalized with an
SV-40 large T retroviral construct were infected with a control
retroviral vector or a vector expressing the oncogenic
Ha-RasV12 mutant and selected for hygromycin resistance
to identify Ras-expressing cells. Extracts were prepared,
and the levels of Ras, p62, and actin, as a loading control,
were determined by immunoblotting. This represents an ex-
periment of at least other two with similar results.
(B–E) In another set of experiments, the number of dead cells
was determined in WT or p62-deficient cells infected with
Ha-RasV12 at 7 d postinfection without antibiotic selection
by trypan blue exclusion (B) and flow cytometry (sub G0;
[C and D]). The percentage of cells in G0/G1 (E) and S+G2/
M (F) was also determined by flow cytometry in these cultures;
results of (B) and (D–F) are the mean ± SD of triplicates.
in the Ras-expressing p62-deficient cells (Fig-
ure 1B), no morphological differences were ob-
served between the two types of Ras transform-
ants, which displayed disorganized multilayered
growth with spindle-shaped, refractile morphology
(Figure 2B). These results indicate that p62 is selec-
tively involved in the control of cell survival during
Ras transformation without affecting the morpho-
logical changes associated with the Ras-induced
transformation process. Nevertheless, the lack
of p62 severely impaired the ability of Ras-transformed cells to
grow in soft agar (Figure 2C), a key characteristic of the trans-
formed phenotype—that is, the size of the colonies obtained in
the Ras-transformed p62 KO cultures were significantly smaller
than those obtained in the Ras-transformed WT cells (Figure 2C,
inset), and the number of colonies was also dramatically reduced
in the KO cells, compared with the WT controls (Figure 2C). Of
note, culturing these cells for long periods led to loss by apopto-
sis of the p62/ Ras-expressing cells (data not shown), consis-
tent with what was observed in the hygromycin-selected clones
(Figure 1A). Collectively, these results demonstrate that Ras
requires p62-derived survival signals to efficiently generate on-
cogenically transformed cells.
Requirement of p62 for Ras-Induced Lung Cancer
in Mice
To address the physiological relevance of p62 for Ras-induced
transformation in vivo, we tested whether p62 is required for
Ras-induced transformation in an in vivo model of carcinogene-
sis. Because oncogenic Ras mutations have been detected in at
least 25% of human lung cancers, and because we observed
p62 overexpression in human lung carcinomas, we tested the
requirement for p62 in a physiologically relevant mouse in vivo
model of Ras-induced lung cancer (Fisher et al., 2001). In these
experiments, we crossed WT and p62 KO mice with bitransgenic
mice that develop pulmonary adenocarcinomas as conse-
quence of the inducible expression of oncogenic Ras in type II
alveolar epithelial cells in response to the presence of doxycy-
cline in the diet (Fisher et al., 2001). These mice are based on
a line of transgenic mice (Clara cell secretory protein [CCSP]-
rtTA) that express the reverse tetracycline transactivator protein
(rtTA) in type II alveolar epithelial cells. The expression of theCancer Cell 13, 343–354, April 2008 ª2008 Elsevier Inc. 345
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of insertion or alterations in the transgene during insertion, be-
cause the CCSP promoter was expected to drive expression
of the tetracycline activator in Clara cells. When we bred these
mice with mice carrying a transgene containing the coding se-
quence for an oncogenic mutant of K-Ras that can be regulated
by rtTA and doxycycline, the result was a bitransgenic mouse
that developed alveolar lesions and pulmonary tumors when
given doxycycline in the drinking water. Hyperplasia of type
II pneumocytes occurred at 14 d after induction with doxycycline
in the WT mice (see Figure S1A available online), whereas solid-
type adenomas and adenocarcinomas were reproducibly de-
tected when doxycycline induction was prolonged for 2 months
(Figures S1B and S1C). This is a physiologically relevant model
for human cancer, because it has been reported that the likely
precursors of lung adenocarcinomas include the type II alveolar
epithelial cells and the Clara cells (Malkinson, 1991). Also, recent
studies demonstrate that expression of oncogenic K-Ras in an
endogenous manner in mice leads to lung adenomas and adeno-
carcinomas in which the likely target cell is the type II pneumo-
cyte, evidenced by the fact that these tumor cells express
Figure 2. Ras-Induced Transformation and Tumori-
genesis Are Inhibited in the Absence of p62
(A) WT and p62-deficient cells were infected with the control
vector or the Ras-expressing construct for 7 d without
hygromycin selection to generate p62-deficient cells that
express oncogenic Ras at levels comparable to those of the
Ras-transduced WT cells.
(B) There were no apparent morphological differences be-
tween WT and p62-deficient Ras transformants. Scale bar,
100 mm.
(C) Lack of p62 severely impaired the ability of Ras-trans-
formed cells to grow in soft agar. The total number of colonies
per plate was scored by counting and represented as mean ±
SD of six plates of two independent experiments; representa-
tive colonies of the two genotypes (inset). Scale bar, 100 mm.
(D) WT and p62 KO mice were crossed with mice that devel-
oped pulmonary adenocarcinomas through inducible expres-
sion of oncogenic Ras in type II alveolar epithelial cells in
response to the presence of doxycycline for 2 or 4 months
(n = 6 per treatment and genotype). Overall tumor burden
was determined by quantification of the tumor area as per-
centage of total area of H&E stainings (left panel). Results
are the mean ± SD. Right panels show representative H&E
stainings. Scale bar, 100 mm.
(E) Positive staining of Ras by IHC in WT and p62-deficient
lungs after 2 months of doxycycline induction (left panel; scale
bar, 50 mm) and Q-PCR quantification of oncogenic Ras ex-
pression (right panel) are shown as mean ± SD. ***p < 0.0001.
surfactant protein C, a clear marker of this type of
cells (Guerra et al., 2003; Tuveson et al., 2004). Im-
portantly, when this experiment was performed in
a p62 KO background, no tumor was detected in
mice treated up to 2 months with doxycycline
(Figure 2D), indicating that p62 is important for
Ras-induced lung cancer. To determine whether
a longer Ras expression could lead to the genera-
tion of lung tumors in the KO mice, we treated these
and WT controls with doxycycline for 4 months, af-
ter which mice were killed and the tumor incidence was deter-
mined by hematoxylin and eosin (H&E) staining of lung sections
as above. As expected, the overall tumor burden and the number
of fully developed adenocarcinomas in the WT mice was higher
than in the 2-month treated WT mice (Figure 2D). Importantly, the
tumor incidence in the KO mice was still dramatically reduced in
the 4-month treatment regimen, and the few tumors detected in
the p62-deficient mice never went beyond the adenoma stage
(Figure 2D, right panels). These are particularly relevant observa-
tions because they demonstrate the importance of p62 for Ras-
induced tumorigenesis in vivo even after a long chronic expres-
sion of Ras. Results shown in Figure 2E demonstrate that Ras
was actually expressed upon doxycycline treatment and that
Ras expression levels in the KO lungs were not lower than in
WT lungs. This control experiment demonstrates that the in-
hibited tumor incidence observed in the p62 KO mice cannot
be explained by lower Ras expression in the mutant lungs.
Effect of p62 Loss in Ras-Induced Cell Signaling
To discern the mechanism underlying the p62 requirement for
survival of Ras-transformed cells, we asked whether the lack346 Cancer Cell 13, 343–354, April 2008 ª2008 Elsevier Inc.
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signaling pathways activated by oncogenic Ras (reviewed in
Downward, 2003; Malumbres and Barbacid, 2003). With this in-
formation, we were able to compare the status of a number of
key signaling intermediaries in extracts from WT or p62 KO cells,
with or without transformation by infection with the oncogenic
Ras retroviral vector. These experiments were performed with
WT and p62 KO cells generated as described previously, without
hygromycin selection, and were analyzed 7 d postinfection,
which leads to comparable Ras levels in both genotypes (Fig-
ure 2A). Under these conditions, Akt activation, as determined
by immunoblotting with an antiphosphoserine 473 Akt/PKB anti-
body, was robustly induced by Ras expression in both WT and
p62-deficient cells (Figure 3A). On the other hand, S6K activity
was not detectably induced by Ras in either WT or p62-deficient
cells (Figure 3A). Ras has also been shown to efficiently activate
the stress-regulated MAPKs, JNK and p38 (Dolado et al., 2007;
Ventura et al., 2004). These two kinases are particularly relevant
because they have been shown to mediate Ras-induced cell
death and, therefore, to have tumor suppressor properties,
at least in some systems (Dolado et al., 2007; Ventura et al.,
2004). We found that Ras-induced activation of activating tran-
scription factor 2 (ATF2) and c-Jun phosphorylation, two bona
fide substrates for JNK and p38, was increased in p62-deficient
cells, compared with similarly treated WT cells (Figure 3B and
3C). These results suggest that the loss of p62 selectively aug-
ments the ability of Ras to activate the phosphorylation of
substrates of the stress-activated MAPKs. This is potentially
Figure 3. Lack of p62 Selectively Alters Ras-Induced Cell Signaling
The activation of Akt (A), S6K (A), ATF2 (B), c-Jun (C), JNK (D), and p38 (E) was
determined in WT and p62 KO EFs expressing similar levels of Ras (Figure 2A).
The activation of JNK and its substrates c-Jun and ATF2 were enhanced in
p62-deficient cells transformed by Ras, compared with their WT controls.
Blots are representative of other two with similar results. Graphs are mean ±
SD of triplicates.important because these kinases have been genetically and
physiologically implicated in Ras-induced cell death (Dolado
et al., 2007; Ventura et al., 2004). Results shown in Figure 3D
demonstrate that Ras-induced JNK phosphorylation was sig-
nificantly increased in p62 KO cells, compared with the WT
controls, whereas the loss of p62 had little or no effect on
the activation of p38 by Ras (Figure 3E). These results demon-
strate that the lack of p62 enhances the ability of Ras to activate
JNK.
Sustained JNK activation has also been implicated in the in-
duction of cell death in TNF-a-treated cells with deficiencies in
the NF-kB pathway. Specifically, RelA/ and IKKb/ cells are
sensitive to TNF-a-induced apoptosis, whereas WT cells are
not. This is, at least in part, due to the fact that NF-kB ablation
allows a sustained activation of JNK (Chang et al., 2006; De
Smaele et al., 2001; Kamata et al., 2005; Nakajima et al., 2006;
Tang et al., 2001), most likely because of the increased ROS pro-
duction by TNF-a in the absence of NF-kB (Pham et al., 2004).
Similarly, increased JNK leads to enhanced ROS production
that further increases JNK activation (Nakano et al., 2006), which
creates a feed-forward loop between both parameters. Ras-in-
duced oncogenic transformation also leads to ROS production,
which can lead to cell death through the activation of JNK (Ven-
tura et al., 2004) and p38 (Dolado et al., 2007). This would serve
to control the survival of transformed cells and the ability of
tumors to progress. Taking into account that NF-kB restrains
ROS production, that ROS are important activators of JNK,
that Ras is a potent inducer of NF-kB, and that p62 has been
shown to be important for the sustained activation of NF-kB,
we reasoned that Ras might induce higher levels of JNK activity
in the absence of p62 through higher ROS production in p62-de-
ficient cells as a consequence of impaired NF-kB activation. To
test this hypothesis, we first measured the levels of ROS in Ras-
transformed WT and p62/ EFs using both fluorimetric and flow
cytometric procedures. Indeed, we found that ROS levels were
significantly higher in p62-deficient EFs than in controls (Figures
4A and 4B). Therefore, we can conclude that the loss of p62
leads to increased ROS production in Ras-transformed cells,
which could account for the higher JNK and apoptosis levels in
p62 KO cells. To determine whether the increased JNK activa-
tion detected in the Ras-transformed KO cells is actually due
to enhanced ROS production, we incubated Ras-transformed
or nontransformed WT and KO cells in the presence or absence
of the ROS scavenger N-acetyl cysteine (NAC). Results shown in
Figure 4C clearly demonstrate that NAC addition reduces the
increase in JNK activity in Ras-transformed KO cells, compared
with WT cells. Similar results were obtained when cells were
treated with butylated hydroxyanisole (BHA; Figure S2). These
results indicate that the enhanced JNK activation induced
by Ras in the absence of p62 is due, at least in part, to increased
ROS production in the KO cells. If this model is correct, we
can predict that JNK activation by ROS induced by adding
H2O2 to the cell cultures would not be affected by the loss
of p62. Results shown in Figure 4D demonstrate that this is, in
fact, the case.
To determine whether increased ROS account for the reduced
viability of the p62 KO cells in the presence of Ras, we incubated
these cells in the absence or in the presence of the ROS scaven-
ger BHA for 3 d, after which the percentage of dead cells wasCancer Cell 13, 343–354, April 2008 ª2008 Elsevier Inc. 347
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clearly demonstrate that BHA blocks the increased cell death
observed in the Ras-expressing p62/ EFs, lending support
Figure 4. Lack of p62 Enhances Ras-Induced ROS Production
(A and B) ROS levels in Ras-transformed WT and p62/ EFs were measured
by using both fluorimetric and flow cytometric (B) procedures.
(C) Phospho-c-Jun levels were determined by immunoblotting of extracts of
WT and p62 KO EFs in the presence or absence of Ras expression and NAC
treatment. Immunoblotting of the lower panel is an actin loading control.
(D) JNK phosphorylation was determined by immunoblotting in WT and KO
cells in response to different doses of H2O2.
(E) Cells were incubated or not with 100 mM BHA for 3 d, after which cell death
was determined by trypan blue exclusion. Experiments shown in (B) and (D) are
representative experiments of at least other two with similar results. Results in
panels (A), (C), and (E) are the mean ± SD of three independent experiments.
Inset in (C) shows one of the three experiments.348 Cancer Cell 13, 343–354, April 2008 ª2008 Elsevier Inc.to the notion that the inability of p62-deficient cells to restrain
ROS production during Ras transformation explains, at least in
part, the lower viability of these cells.
Because ROS levels are normally kept under control by the
products of NF-kB-inducible genes, we next determined
whether the loss of p62 would affect NF-kB activation by Ras.
Figures 5A and 5B show that the expression of bona fide NF-
kB-dependent genes in Ras-expressing EFs was severely im-
paired by the lack of p62. Of particular relevance are the levels
of ferritin heavy chain (FHC; Figure 5B), which has been reported
to be an ROS scavenger whose expression is regulated by NF-
kB (Pham et al., 2004). Collectively, these results demonstrate
that p62 is important for the expression of NF-kB-dependent
genes by Ras, including the ROS scavenger FHC. To determine
whether p62 is required for the activation of NF-kB, we trans-
fected HeLa cells with a kB-dependent luciferase reporter, along
with a plasmid control or a Ras-expressing vector, with or with-
out a p62 antisense construct that was previously described by
our laboratory (Sanz et al., 1999, 2000). Transfection of the p62
antisense construct severely impaired NF-kB activation by Ras
(Figure 5C). Figure 5D shows the impairment in Ras-induced
kB-dependent reporter activity in KO EFs, compared with that
in the WT controls. Of note, reintroduction of p62 into the KO
cells restores the ability of Ras to activate FHC (Figure 5B and
Figure S3) and kB-dependent transcription (Figure 5D and
Figure S3). These observations clearly suggest that p62 is re-
quired for Ras-induced NF-kB activation, which promotes cell
survival by reducing ROS levels and JNK activity. Recent data
demonstrate that Ras activates NF-kB through IKK activation
(Arsura et al., 2000). Because p62 is important for the stimulation
of NF-kB in response to Ras (Figures 5A–5D), we tested the hy-
pothesis that p62 is the functional link between Ras and activa-
tion of the IKK complex. For this, extracts from Ras-transformed
or nontransformed WT and KO EFs were immunoprecipitated
with an anti-IKKg antibody, after which IKK activity was deter-
mined in the immunoprecipitates. The presence of Ras resulted
in activated IKK in WT EFs, but this was not the case in p62 KO
cells, where the level of Ras-activated IKK was inhibited
(Figure 5E). This indicates that p62 is a relevant functional link be-
tween Ras and NF-kB at the level of IKK activation. Collectively,
these results, in conjunction with those shown in Figures 3 and 4,
demonstrate that the lack of p62 impairs NF-kB activation in
Ras-transformed cells, which leads to higher ROS levels and in-
creased cell death, which accounts for the lower tumorigenic po-
tential of the p62/ cells (Figures 1 and 2). We next determined
whether the loss of p62 impairs the ability of Ras to promote the
nuclear translocation of NF-kB. Results shown in Figure 5F
clearly demonstrate the inhibition of Ras-induced p65 (RelA) nu-
clear translocation in KO EFs, compared with the WT control. To
determine whether NF-kB is actually activated in the lungs ex-
pressing the oncogenic Ras and to determine whether this needs
p62, we stained sections from WT and KO lungs expressing or
not Ras (Figure 2E) with an anti-RelA antibody and scored for
number of cells showing nuclear staining of RelA. To make a bet-
ter comparison between WT and KO samples, we focused in the
regions free of tumors in the WT lungs (Figure S4). The data
shown in Figure 5G demonstrate that Ras actually triggers the
nuclear translocation of RelA in lung, as well as that the lack of
p62 severely impairs that parameter.
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(A and B) IL-6 (A) and (B) FHC mRNA levels were determined by Q-PCR in WT
and p62-deficient EFs in the presence or absence of Ras expression. p62-KO
EFs were reconstituted with p62 by retroviral transduction.
(C) kB-transcriptional activity was determined in HeLa cells transfected with
a kB-dependent luciferase reporter plasmid along with a plasmid control or
a Ras expression vector, with or without p62 antisense.
(D) EFs WT, KO, and KO-p62 were transfected with the kB-luciferase reporter
as above.
(E) Cell extracts from WT and p62-deficient EFs infected were immunoprecip-
itated with an anti-IKKg antibody, and IKK activity was determined.
(F) NF-kB activation was determined in WT or KO EFs either transfected or not
with oncogenic HA-tagged Ras, followed by immunofluorescence staining
with anti-p65 and anti-HA antibodies, and TO-PRO nuclear staining (left panel;
scale bar, 20 mm). The percentage of p65 nuclear-positive cells was deter-
mined by counting ten fields of each experimental condition (right panel).
Results are the mean ± SD.
(G) Sections from WT and KO lungs expressing or not Ras were stained with an
anti-RelA antibody and scored for number of cells showing nuclear staining of
RelA. Results are the mean ± SD of five different sections per mouse of a total
of six mice in each condition.
(H) The phosphorylation state of IKKa/b was determined in the same extracts
as in (E) by immunoblotting with a phosphospecific antibody.Previous studies from our and other laboratories demonstrated
biochemically and genetically that p62 is required for IKK activa-
tion (Duran et al., 2004; Martin et al., 2006). The data reported
here are important because they represent the identification of
p62 as a regulator of Ras signals leading to IKK activation, and
they constitute a mechanistic explanation of how Ras regulates
NF-kB. A critical question that arises from these studies concerns
the precise molecular interactions whereby p62 channels Ras
signals for the activation of NF-kB. In this regard, two protein
modifications have been reported to be critical in IKK activation
in response to other stimuli: IKKb phosphorylation and the K63
polyubiquitination of IKKg, receptor-interacting protein 1 (RIP1),
and TRAF6 (Chen, 2005; Ghosh and Karin, 2002). RIP1 ubiquiti-
nation occurs in response to TNF-a, and TRAF6 ubiquitination
is activated by IL-1. IKKg ubiquitination, on the other hand, has
been reported in in vitro overexpression experiments and in
response to signals emanating from the T-cell receptor (TCR) in
T cells (Chen, 2005; Zhou et al., 2004). To determine which of
these parameters are activated by Ras and which require p62,
we analyzed the phosphorylation state of IKKb by using an anti-
phospho-IKKa/b antibody in cell extracts from Ras-transformed
or nontransformed WT and p62 KO EFs. Figure 5H shows that
Ras significantly activates IKKb phosphorylation in WT EFs.
Also, although Ras-induced IKKa/b phosphorylation was detect-
able in the KO cells, it was significantly reduced, compared with
that in WT cells (Figure 5H). Because p62 has been shown,
biochemically and genetically, to be linked to TRAF6, we next
determined whether the lack of p62 affects the ability of Ras to
promote TRAF6 polyubiquitination. WT and KO cells, with or
without Ras transformation, were immunoprecipitated with an
anti-TRAF6 antibody, and the immunoprecipitates were analyzed
with an anti-ubiquitin antibody. Interestingly, although TRAF6
was dramatically polyubiquitinated in the WT Ras transformants,
this effect was completely abolished in the p62 KO cells (Fig-
ure 5I). These results are consistent with the proposed role of
p62 in TRAF6 polyubiquitination in other systems (Martin et al.,
2006; Wooten et al., 2005) and demonstrate that p62 is essential
for the ability of Ras to activate this parameter. Because TRAF6
polyubiquitination has been implicated in IKK activation, these
results could account for the role of p62 in Ras-induced IKK ac-
tivation. Intriguingly, no RIP1 or IKKg polyubiquitination was ob-
served in response to Ras in WT or in p62-deficient EFs (data not
shown), suggesting that, at least in this system, IKK can be acti-
vated without IKKg polyubiquitination and that RIP1 is probably
not a target of Ras signaling.
Increased p62 Levels in Ras-Transformed Cells
and Human Tumors
Once the role of p62 in NF-kB activation and transformation by
Ras has been established, we sought to gain insights into the
mechanism whereby Ras actions are linked to p62. Data shown
in Figure 1A and Figure 6A demonstrate that Ras expression
(I) These extracts were also immunoprecipitated with an anti-TRAF6 antibody,
and the immunoprecipitates were then analyzed for polyubiquitination with an
antiubiquitin antibody. Ras and actin levels were determined by immunoblot.
These are representative experiments of at least other two with similar results.
Results in (A–D) are the mean ± SD of triplicates.Cancer Cell 13, 343–354, April 2008 ª2008 Elsevier Inc. 349
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tence of a signaling connection between these two molecules.
Interestingly, the expression of a nontransforming dominant
negative mutant of Ras not only did not induce p62 but even
provoked a significant reduction in the levels of this protein (Fig-
ure 6A). To determine whether these observations are relevant to
human cancers, we analyzed whether p62 overexpression was
a general phenomenon associated with tumor transformation
in humans by examining the expression of p62 in a panel of cor-
responding normal and tumor-derived tissue extracts. We
probed the membrane of a protein microarray with a highly spe-
cific monoclonal antibody to human p62 and actin as a control.
Quantitation of p62 expression in each tumor tissue, compared
with their respective normal controls, revealed that p62 protein
levels were increased in a highly significant number of cancers
Figure 6. Induction of p62 by Ras and Increased Expression in
Human Tumors and Cancer Lines
(A) p62 levels were increased in EFs infected with RasV12 but not with RasN17.
Actin and Ras levels were also determined by immunoblot in the same ex-
tracts.
(B) Lung adenocarcinomas, but not squamous cell carcinomas, show overex-
pression of p62, compared with normal lung tissue.
(C) IMR90 and A549 cells, treated with a control siRNA or with two p62 specific
siRNAs, were analyzed for viability by trypan blue exclusion and for p62 and
Ras levels, as described in Experimental Procedures; results are the mean ±
SD of triplicates.350 Cancer Cell 13, 343–354, April 2008 ª2008 Elsevier Inc.(Figure S5). In lung, p62 levels were overexpressed in adenocar-
cinomas but not in squamous cell carcinomas (Figure 6B and
Figure S5). Interestingly, Ras mutations are often associated
with the former but rarely to the latter kind of tumors (Bos,
1989). To further address the role of p62 in human lung cancer,
we have analyzed p62 levels and its requirement for survival of
the human lung cancer cell line A549, compared with nontrans-
formed IMR90 cells. Immunoblot analysis demonstrates that
A549 cells display higher p62 levels than do the IMR90 controls
(Figure 6C, lower panels). We next used two different siRNA to
deplete p62 levels in these cells and determined whether that
affects their viability. Interestingly, both siRNAs effectively de-
pleted cellular p62 levels (Figure 6C, lower panels), but they
only increased cell death in the tumor cell line (Figure 6C, upper
panel). Of note, the siRNA2 was the most efficient in depleting
p62 levels and, interestingly, was the one that also more effi-
ciently induced cell death (Figure 6C). On the basis of all these
observations, it seems that p62 overexpression is a phenomenon
associated with cancer and, in the case of lung cancer, is likely
linked to Ras mutations. Although a more comprehensive analy-
sis of p62 expression in human cancer samples is necessary to
definitively assess the prevalence of p62 expression in human
tumors, these data strongly suggest that our results in Ras-trans-
formed EFs and mice are of physiological relevance.
Mechanism of p62 Induction by Ras
To investigate the mechanism of p62 induction by Ras, we
initially determined whether Ras induction of p62 is at the
mRNA level. WT EFs, both expressing and not expressing Ras,
were lysed; RNA was extracted and analyzed for levels of p62
mRNA by Q-PCR. Results shown in Figure 7A demonstrate
that Ras expression leads to increased p62 mRNA levels, inter-
estingly, in a manner that depends on the MEK and PI 3-kinase
pathways. These data are of special relevance because Ras-in-
duced activation of IKK has previously been reported to rely on
these same two pathways (Arsura et al., 2000), further support-
ing the notion that p62 is the previously unidentified link between
Ras and NF-kB activation. Consistently, inhibition of transcrip-
tion by treating cells with DRB (5,6-dichloro-1-b-D-ribobenzimi-
dazole) completely reduced p62 mRNA levels (Figure 7B),
strongly suggesting that Ras induction of p62 mRNA is at a
gene transcriptional level. To determine the precise mechanism
whereby Ras regulates p62 transcription, we cloned 1808 bp of
the p62 promoter (Figure S6), which were subcloned into a lucif-
erase reporter plasmid to further establish the role of transcrip-
tion in Ras-induced p62 mRNA levels (Figure 7C). Interestingly,
Ras expression provokes a dramatic induction of luciferase
activity (Figure 7D), indicating that Ras induces the activity of
the p62 promoter. This demonstrates that the p62 increased
levels in Ras-expressing cells can be accounted for by changes
at a gene transcriptional level as consequence of Ras-induced
signals acting on the p62 promoter. To identify the enhancer
elements in the p62 promoter responsible of the induction by
Ras, we next constructed different 50 deletions of the p62 pro-
moter (Figure 7C and Figure S6). Experiments with deletions 1,
2, and 3 (Figure 7C) demonstrate that the region encompassing
nucleotides 1808 to 1428 contains potential Ras-responsive
regulatory elements (Figure 7D). That region contains one activa-
tor protein (AP)-1 and one kB element (Figure S6). To establish
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activity, we transfected control and Ras-expressing cells with lu-
ciferase reporter vectors containing p62 promoter deletions 4 and
5 starting at nucleotides 1732 and 1656 (Figure 7C). Impor-
tantly, the simple deletion of the region encompassing nucleotides
1808 to1732, which contains the AP-1 enhancer element, was
sufficient to abolish the activation of the p62 promoter by Ras
(Figure 7E). A point mutant in the AP-1 enhancer element severely
abolished the p62 promoter activation by Ras (Figure 7F). This
indicates that the AP-1 enhancer element is responsible of the
Ras ability to induce p62 promoter activity.
DISCUSSION
The balance between survival and death is critical for the control
of tumor progression. The ability of Ras to promote cell survival is
essential for the suppression of apoptosis associated with Ras-
induced transformation and, therefore, for cancer initiation and
progression (Hanahan and Weinberg, 2000). The NF-kB pathway
is central to this prosurvival function of Ras (Mayo et al., 2001).
This, along with the Akt-initiated cascade (Downward, 2003),
provides independent signals that inhibit cell death. Several
mouse models have demonstrated the in vivo role of NF-kB in
cell survival and in cancer initiation and progression (Greten
et al., 2004; Rakoff-Nahoum and Medzhitov, 2007), as well as
the role of PI 3-kinase-derived signals in Ras-induced lung can-
Figure 7. Transcriptional Mechanism of
Ras-Induced p62 Levels
(A) Control and Ras-expressing cells were incu-
bated for 5 hr with or without PD98059 (PD) or
wortmannin (W), and p62 mRNA levels were then
determined by RT-PCR.
(B) Control and Ras-infected cells were incubated
in the absence or in the presence of DRB for differ-
ent times to block transcription, and p62 mRNA
levels were determined as above.
(C) Schematic representation of the different lucif-
erase reporter constructs of the p62 promoter.
(D and E) Analysis of p62 promoter in response to
Ras. HeLa cells were transfected with the different
luciferase reporter constructs with different doses
of control plasmid or Ras-expressing vector, and
luciferase activity was measured as described in
Experimental Procedures.
(F) A point mutation was introduced in the AP-1
enhancer element of the p62 promoter, and its
activity in response to Ras was determined as de-
scribed above. These are mean ± SD of triplicates.
cer (Gupta et al., 2007). Our own results
in p62 KO mice demonstrate that p62 is
required for Ras-induced lung cancer.
Additional non-cell-autonomous factors
could, at least theoretically, come into
play in the in vivo environment. However,
our cell culture experiments reported here
clearly demonstrate a role for p62 in NF-
kB and cell survival during Ras-induced
transformation and strongly suggest that
the simplest explanation for the failure of
tumors to develop in p62 KO mice is that lung epithelial cells ex-
pressing activated Ras fail to activate NF-kB, which is directly re-
quired for their survival. Our data in Figure 5G demonstrate that
Ras-induced RelA nuclear translocation in lung cells is severely
inhibited in p62 KO mice and are consistent with, and supportive
of, this notion. Moreover, the fact that we see the same effect in
EFs (Figure 5F) strongly supports the concept that there is a ma-
jor cell-autonomous component to the ability of p62 deficiency to
inhibit NF-kB and Ras-induced lung cancer in vivo.
The activation of NF-kB by Ras has long been recognized.
However, the mechanisms controlling this important event re-
mained unclear. Interestingly, recent studies presented convinc-
ing evidence indicating that IKK activation by Ras requires the
combined action of extracellular signal-regulated kinase (ERK)
and Akt signals, although how these translate into IKK activation
was not determined (Arsura et al., 2000). Here, we show that the
signaling adaptor p62 is required for Ras-induced transformation
and NF-kB activation both in vitro and in an in vivo model of
inducible lung tumorigenesis. Interestingly, p62 is induced by
Ras at the mRNA level through an ERK- and Akt-dependent
pathway, by a mechanism that involves the transcriptional regu-
lation of the p62 promoter. Specifically, we show that a fragment
encompassing an AP-1 enhancer element is required for p62
transcriptional activation by Ras. These observations are clearly
consistent with the notion that p62 is the missing link between
Ras and IKK activation, because IKK activation has also beenCancer Cell 13, 343–354, April 2008 ª2008 Elsevier Inc. 351
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tantly, because we show here that p62 is actually necessary for
Ras-induced IKK activation. Therefore, the mechanism whereby
Ras induces NF-kB clearly involves its ability to activate IKK
through p62. This explains why p62 is necessary for Ras-in-
duced transformation, because the absence of NF-kB is known
to impair the transforming ability of Ras as the result of the loss of
an important survival pathway that antagonizes Ras induction of
cell death. Whether the induction of p62 is required for Ras to ac-
tivate NF-kB, or whether basal p62 levels are sufficient for that
effect and the induction of p62 is a way to amplify the Ras signal,
cannot be concluded from these studies. However, the fact that
p62 is upregulated by Ras, together with the fact that p62 levels
are increased in human tumors, suggests that the enhanced
levels of p62 are likely to be important, if not for tumor initiation,
at least for tumor progression.
The critical observations reported here lead to the question of
how p62 channels Ras signals toward IKK. We have previously
demonstrated that p62 is part of several signaling complexes
that are reportedly essential for IKK activation through the signal-
ing adaptor protein TRAF6. Specifically, p62 binds TRAF6 in at
least four different cellular settings: (1) the interleukin-1-triggered
Myd88/IRAK complex (Sanz et al., 2000); (2) the TCR-activated
Bcl10/Malt-1 signalsome cassette (Martin et al., 2006); (3) recep-
tor activatory of NF-kB (RANK) in RANKL-activated osteoclasts
(Duran et al., 2004); and (4) the nerve growth factor (NGF) recep-
tor system (Wooten et al., 2005). This is important because
TRAF6 is an E3 ubiquitin-ligase that promotes K63-polyubiquiti-
nation of many proteins, including itself (Chen, 2005). Although
the mechanism is not entirely clear, that ubiquitination process
creates a number of docking sites that are necessary for IKK
activation. We have shown that p62 is critically involved in the
oligomerization of TRAF6 (Sanz et al., 2000; Wooten et al.,
2005), which is an essential step for these polyubiquitinations
(Chen, 2005). In addition to K63-polyubiquitination, IKK activa-
tion correlates with the phosphorylation of both catalytic sub-
units (IKKa and IKKb) at their activation loops (Ghosh and Karin,
2002). Recent results suggest that these are separate required
events that independently are not sufficient to trigger IKK activity
(Grabiner et al., 2007; Misra et al., 2007; Su et al., 2005). We have
shown here that the lack of p62 significantly reduces the ability of
Ras to induce IKKa/b phosphorylation and completely abolishes
the polyubiquitination of TRAF6. The latter finding indicates that
p62 induction by Ras activates TRAF6 E3-ubiquitin ligase activ-
ity. On the other hand, RIP1 ubiquitination, which is important for
TNF-a-induced IKK activation (Ea et al., 2006), was not induced
by Ras (data not shown). Our previous results showed that p62
associates with RIP1 in TNF-a-activated cells (Sanz et al.,
1999). However, the genetic inactivation of p62 does not seem
to affect TNF-a signaling, at least in fibroblasts, indicating that al-
though p62 is essential for TRAF6-mediated signaling toward
NF-kB in several cell systems (Duran et al., 2004; Martin et al.,
2006), p62 might be redundant for RIP1 function. On the other
hand, we did not see any Ras-induced IKKg polyubiquitination
(data not shown). This suggests that Ras regulates IKK activation
through a mechanism that most likely involves the TRAF6 E3-ubiq-
uitin ligase activity but not the ubiquitination of IKKg. However,
we cannot completely rule out that IKKg ubiquitination is induced
by Ras at levels below the detection capability of the methods352 Cancer Cell 13, 343–354, April 2008 ª2008 Elsevier Inc.used here. In this regard, it should be noted that IKKg polyubiqui-
tination is readily detectable in overexpression experiments, but
that recent studies illustrate the difficulty of measuring the endog-
enous activation of this parameter (Grabiner et al., 2007).
The defect in NF-kB activation that we observed in p62/
cells is relevant to their resistance to transformation by Ras.
Among the different antiapoptotic signals delivered by NF-kB
is the expression of genes involved in ROS scavenging, such
as ferritin heavy chain (FHC; Pham et al., 2004). In this regard,
our results strongly demonstrate that the loss of p62 impairs
FHC expression and provide a likely explanation for why Ras
transformation leads to higher ROS levels in p62 KO cells than
in WT cells. This enhanced ROS production could explain why
JNK activity is enhanced in the absence of p62, because it has
been demonstrated that ROS is capable of inactivating phos-
phatases that keep JNK under control (Kamata et al., 2005). In
addition, elevated JNK activity induces the production of more
ROS (Nakano et al., 2006), activating a positive feedback cycle
that is deleterious for the viability of the transformed cell, and
explains the lack of cell toxicity in JNK-deficient Ras-trans-
formed cells (Ventura et al., 2004). Our data are clear in that
the inhibition of ROS restores cell viability in the p62-deficient
Ras transformed cells.
In summary, we have identified p62 as target of Ras regulation
of cell transformation. This mediation of Ras signaling relies on
p62’s ability to channel signals toward IKK activation and on
the subsequent expression of survival genes, including those
involved in the regulation of ROS induction and JNK activation.
These are two interconnected elements that promote cell death
during oncogenic transformation by Ras. Because p62 has been
shown genetically and biochemically to play an essential role in
the sustained activation of NF-kB in two settings unrelated to
cancer, namely osteoclast differentiation and Th2 cell polariza-
tion, these results not only solve an important conundrum with
regard to the precise mechanism whereby Ras activates NF-
kB but also illustrate how oncogenes might impinge on pathways
used by other signaling cascades and take advantage of them to
ensure the survival of the transformed cell.
EXPERIMENTAL PROCEDURES
Mice
The p62KO, CCSP-rtTA, and K-Ras (Tet-op-K-RasG12D) transgenic mice were
described elsewhere (Duran et al., 2004; Fisher et al., 2001). All mice were born
and kept under pathogen-free conditions. Animal handling and experimental
procedures conform to institutional guidelines (University of Cincinnati Institu-
tional Animal Care and Use Committee). All genotyping was done by PCR.
Doxycycline was administered via drinking water freshly prepared twice
a week, at a concentration of 500 mg/l.
Histological Analysis
Lung were inflated, excised, fixed in 10% neutral buffer formalin for 24 hr,
dehydrated, and embedded in paraffin. Sections (5 mm) were cut and stained
with H&E. Overall tumor burden was quantitated by measuring tumor area
in H&E-stained sections using NIH ImageJ (version 1.38; http://rsb.info.nih.
gov/ij/). Immunohistochemistry was performed with anti-Ras (F-132; 1:50 dilu-
tion) and anti-p65 (C-20; 1:100 dilution) antibodies from Santa Cruz. Sections
were deparaffinized and rehydrated, and antigen retrieval was performed with
10 mM citric acid and 2 mM EDTA (pH 6.2) with boiling for 10 min. After
quenching of endogenous peroxidase and blocking in normal serum, tissues
were incubated with primary antibody overnight at 4C, followed by incuba-
tion with biotinylated secondary antibody. Antibodies were visualized with
Cancer Cell
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as a chromagen. Slides were then counterstained with hematoxylin, dehy-
drated, and mounted.
Determination of ROS Levels
Proliferating cells were washed once with warm PBS and were incubated with
10 mM 20-70-dichlorodihydrofluorescein diacetate (DCF-DA, Molecular Probes)
in warm PBS supplemented with 5.5 mM glucose. After 10 min at 37C, PBS
was replaced with complete culture medium, and cells were incubated for
an additional 10–15 min, washed once again with warm PBS, trypsinized,
and analyzed by FACS (FACS Calibur, BD) or in a fluorimeter (LS55-Luminis-
cence Spectrometer, Perkin Elmer).
Cell Cycle Analysis
Cell cycle analysis was determined by flow cytometry, as described elsewhere
(Barradas et al., 1999). Briefly, cells were seeded in p6-wells in DMEM contain-
ing 10% FCS. After different treatments according to the experiments,
medium was collected, and cells were trypsinized and fixed in 70% ethanol.
After fixation, cells were stained with propidium iodide (50 mg/ml) in a solution
containing 0.05% Triton X-100 and 0.1 mg/ml RNase A. Cells were then ana-
lyzed in an EPICS XL flow cytometer (Coulter Electronics Inc.) and ModFit LT
Software (Verity).
Western Blot
Cell extracts for western blot were prepared in RIPA buffer (13 PBS, 1%
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM phenyl methyl
sulfonyl fluoride, and protease inhibitors). Lysates were separated by SDS-
PAGE and were transferred to nitrocellulose-ECL membranes (GE Healthcare);
the immune complex was detected by chemiluminescence (GE Healthcare).
Western blot of the commercially available human cancer protein array (Bio-
chain A1235713-1) was performed according manufacturer’s instructions
with anti-p62 antibody. These studies were approved by the University of
Cincinnati Institutional Review Board #1-2.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures and
six supplemental figures and can be found with this article online at http://
www.cancercell.org/cgi/content/full/13/4/343/DC1/.
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